FWB 1313
Alternative Names: FWB-1313Latest Information Update: 20 Oct 2021
At a glance
- Originator Shenzhen Forward Pharmaceutical
- Class
- Mechanism of Action Interleukin 13 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 12 Oct 2021 Preclinical trials in Immunological disorders in China (Parenteral) (Shenzhen Forward Pharmaceutical pipeline, October 2021)